From November 4th to 6th, 2024, a delegation from Beijing Genecradle Therapeutics Technology Co., Ltd. (hereinafter referred to as "Genecradle Therapeutics") traveled to Stockholm, Sweden, to attend the highly anticipated 2024 BIO-Europe Autumn Conference. As the largest biotechnology event in Europe, the conference attracted over 2,800 companies and 5,500 life science experts from more than 60 countries worldwide, serving as a crucial platform for exchange and cooperation in the biopharmaceutical industry.

During the conference, Genecradle Therapeutics actively engaged in one-on-one business negotiations, striving to explore business expansion possibilities with cutting-edge enterprises in the international biopharmaceutical industry. The company highlighted the latest research achievements and progress of several independently developed gene therapy drugs, particularly the innovative treatment plans and significant clinical effects of AAV vector gene therapy drugs—GC101, GC301, and GC304 injections for spinal muscular atrophy (SMA), Pompe disease, and hypertriglyceridemia (HTG), which garnered widespread international attention and in-depth discussions.

Through this conference, Genecradle Therapeutics showcased China's innovative strength in the field of gene therapy to the world and actively promoted interaction and exchange with international peers, seeking opportunities for cooperation. Genecradle Therapeutics looks forward to working alongside global partners to advance innovation and development in the life sciences and contribute to the health and well-being of patients worldwide.

Dr. Wang Xiaodong, Head of International Cooperation at Genecradle Therapeutics (top left), and the conference scene